Organoid facility

Organoids for pioneering research and therapeutic innovations through cutting-edge bioprocessing.

At OBBI, we focus on enabling groundbreaking advancements on organoids, to drive innovation in research, diagnostics, and therapeutic development.

What are organoids?

Organoids are three-dimensional, miniature, and simplified avatars of organs that are grown in vitro from stem cells or progenitor cells. These structures mimic the cellular heterogeneity and organization of organs and display at least one function of their corresponding mature organs, making them valuable tools for research in developmental biology, disease modelling, drug discovery, drug testing, and personalized medicines. Our facility leverages advanced bioproduction methods to ensure high-quality, reproducible organoid systems that align with research and demands from the industry.

Our offerings include also tumoroids and spheroids. Tumoroids are three-dimensional tumor models derived from patient tumor tissues or cancer cell lines, providing an invaluable tool for studying tumor biology and evaluating anti-cancer therapies. Spheroids are simplified 3D aggregates of cells that mimic the in vivo environment, often used for drug screening and basic biological research. Together, these systems expand our comprehensive service portfolio, addressing a broad spectrum of research and therapeutic needs.

OBBI is strategically designed to support organoid, tumoroid, and spheroid development, from basic research to clinical applications. Our commitment to excellence ensures that every model meets the highest standards of viability, scalability, and regulatory compliance, solidifying our position as a leader in micro-physiological system bioproduction.

Services

OBBI focuses on providing, developing, and advancing organoid models both disease-specific and normal tissue models, to enable pre-clinical studies and pathogenesis research.

These comprehensive services aim to advance the use of organoids together with tumoroid and spheroid technologies in biotechnology, enhancing research capabilities and enabling innovative therapeutic solutions.

Organoid models on a shelf and on-demand

The current and ongoing organoid models include :

Human and murine colorectal organoids: Models derived from colorectal tumors and chronic inflammatory conditions (e.g., IBD).
Bladder organoids.
Fallopian tract organoids.
Pre-vascularized human adipose organoids from millimetric to centimeter scale
Pre-vascularized human mesenchymal organoids

All these models are immediately available and can be improved according to the different service targets Additional models are available within our network upon request and customized organoid models can be developed in partnership to meet specific research or pre-clinical needs.

Complexification and higher-order model systems

Incorporation of microbiome, vascular, and immune system components.
Improvement of organoid maturity
Integrating organoids into higher-order model systems such as Organoid-on-a-Chip (OOC). A miniaturized system that integrates an organoid with microfluidic technology to address the effect of the microenvironment to the organoid functionality.
Body-on-a-Chip strategies: developing interconnected organoid systems to study multi-organ interactions and systemic effects.
Supporting research in pharmacokinetics, disease modelling, and personalized medicine with advanced chip technologies.

Developing workflow processes to enable comprehensive screening services

OBBI provides robust and comprehensive screening services designed to evaluate the safety and efficacy of therapeutic candidate compounds. By leveraging advanced organoid models that closely mimic human tissue physiology, these services enable the identification of potential toxic effects in a controlled and reproducible environment.

High-throughput screening methods combined with precise analytical tools ensure thorough assessments, including cellular viability, structural integrity, and functional responses.
This approach not only accelerates preclinical drug development but also reduces the reliance on traditional animal testing, offering more predictive and reliable insights into human-specific toxicity and therapeutic performance.

Cryopreservation and biobanking

Cryopreservation is a critical technique in organoid bioproduction, enabling the long-term storage, transportation, and scalability of organoid cultures without compromising their quality, functionality, or viability. By implementing robust cryopreservation strategies, OBBI ensures the accessibility, consistency, and quality of organoid models, supporting the needs of both academic research and industrial applications.

Development of standardized cryopreservation protocols tailored to specific organoid types.
Post-Thaw Quality Controls
Access to our facility ongoing biobanks.
Creation of tailored prospective biobank collections, including disease-specific and healthy organoid models

Basic and advanced Quality Controls

We offer a range of standardized services. For more information, please refer to the ‘Quality Controls’ section.

Standard Quality Controls
Advanced characterization
Integration of analytical tools & Artificial Intelligence (AI)
Regulatory compliance

applications domains

Organoid technology presents several significant market opportunities within the biotech and pharmaceutical industries, driven by its advanced capabilities in mimicking human organ structures and functions for various applications.